Pluvicto Therapy

 

Pluvicto (Lu-177 vipivotide tetraxetan) Therapy

Pluvicto is a radioligand therapeutic agent indicated for the treatment of adult patients with prostate- specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy. This treatment is available at the Medical University of South Carolina (MUSC)-Health Charleston Campus in the Nuclear Medicine Theranostic Suite.

Pluvicto is given as an intravenous (IV) infusion. A full course of therapy is six doses of Pluvicto given 6 weeks apart. Therapy plans may vary depending on how your body responds to the treatment.

Patients referred for therapy should have a recent PSMA PET-CT showing evidence of PSMA avid metastatic disease, appropriate blood counts, renal function, and liver function. Requests for therapy will be reviewed by MUSC nuclear medicine physicians to determine treatment eligibility. Insurance eligibility will also be completed prior to scheduling.

Please contact RN Patient Care Coordinator Jenny Hill MSN, RN at 843-792-9626 to begin the referral process and to obtain the referral form.

Patient information and education can be found at the following link:  https://www.hcp.novartis.com/products/pluvicto/psma-positive-mcrpc/resources-for-your-patients/